Literature DB >> 28870832

Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.

Kruti S Soni1, Fan Lei1, Swapnil S Desale1, Luis A Marky2, Samuel M Cohen3, Tatiana K Bronich4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28870832      PMCID： PMC5632592          DOI： 10.1016/j.jconrel.2017.08.038

Source DB:  PubMed          Journal:  J Control Release        ISSN： 0168-3659            Impact factor:   9.776


× No keyword cloud information.
  43 in total

1.  Fluorescence probes for critical micelle concentration determination.

Authors:  E D Goddard; N J Turro; P L Kuo; K P Ananthapadmanabhan
Journal:  Langmuir       Date:  1985-05       Impact factor: 3.882

2.  Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

Authors:  Nivedita Sain; Bhavani Krishnan; Michael G Ormerod; Assunta De Rienzo; Wai M Liu; Stanley B Kaye; Paul Workman; Ann L Jackman
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

3.  Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor.

Authors:  Yuki Mochida; Horacio Cabral; Yutaka Miura; Francesco Albertini; Shigeto Fukushima; Kensuke Osada; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  ACS Nano       Date:  2014-06-13       Impact factor: 15.881

4.  Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate).

Authors:  J E Chung; M Yokoyama; M Yamato; T Aoyagi; Y Sakurai; T Okano
Journal:  J Control Release       Date:  1999-11-01       Impact factor: 9.776

5.  Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization.

Authors:  Zhang Wei; Junguo Hao; Shi Yuan; Yajuan Li; Wu Juan; Xianyi Sha; Xiaoling Fang
Journal:  Int J Pharm       Date:  2009-05-03       Impact factor: 5.875

6.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Authors:  David B Solit; S Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J Morris; Susan F Slovin; W Kevin Kelly; Anthony DeLaCruz; Tracy Curley; Glenn Heller; Steven Larson; Lawrence Schwartz; Merrill J Egorin; Neal Rosen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

7.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Authors:  Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506

8.  Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

Authors:  Reiki Nishimura; Yasuhiro Okumura; Nobuyuki Arima
Journal:  Breast Cancer       Date:  2008       Impact factor: 4.239

9.  Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect.

Authors:  Bart S Hendriks; Stephan G Klinz; Joseph G Reynolds; Christopher W Espelin; Daniel F Gaddy; Thomas J Wickham
Journal:  Mol Cancer Ther       Date:  2013-05-30       Impact factor: 6.261

10.  Polymeric micelles based on poly(ethylene glycol) block poly(racemic amino acids) hybrid polypeptides: conformation-facilitated drug-loading behavior and potential application as effective anticancer drug carriers.

Authors:  Peng Fei Gu; Hui Xu; Bo Wen Sui; Jing Xin Gou; Ling Kuo Meng; Feng Sun; Xiu Jun Wang; Na Qi; Yu Zhang; Hai Bing He; Xing Tang
Journal:  Int J Nanomedicine       Date:  2012-01-05
View more
  3 in total

1.  Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.

Authors:  Gaofeng Liang; Yanliang Zhu; Doulathunnisa Jaffar Ali; Tian Tian; Huantian Xu; Ke Si; Bo Sun; Baoan Chen; Zhongdang Xiao
Journal:  J Nanobiotechnology       Date:  2020-01-09       Impact factor: 10.435

2.  Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer.

Authors:  Fan Lei; Xinyuan Xi; Satyanarayana Rachagani; Parthasarathy Seshacharyulu; Geoffrey A Talmon; Moorthy P Ponnusamy; Surinder K Batra; Tatiana K Bronich
Journal:  J Control Release       Date:  2020-11-18       Impact factor: 9.776

3.  Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.

Authors:  Anne Rodallec; Jean-Michel Brunel; Sarah Giacometti; Helene Maccario; Florian Correard; Eric Mas; Caroline Orneto; Ariel Savina; Fanny Bouquet; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino
Journal:  Int J Nanomedicine       Date:  2018-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.